Afshin Dowlati, MD

home / authors / afshin-dowlati-md

Articles

September 27th 2024

Established Multidisciplinary Therapies for SCLC

Ryan Haumschild, PharmD, MS, MBA Anne Chiang, MD, PhD Afshin Dowlati, MD Jacob Sands, MD Wade Iams, MD

Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.

September 27th 2024

Introduction: Risk Factors and Characteristics Defining SCLC

Ryan Haumschild, PharmD, MS, MBA Anne Chiang, MD, PhD Afshin Dowlati, MD Jacob Sands, MD Wade Iams, MD

Panelists discuss how small cell lung cancer (SCLC) differs from non–small cell lung cancer in terms of staging, epidemiology, risk factors, prevention strategies, and prognosis, while also exploring the distinctions between limited-stage and extensive-stage SCLC and considering potential improvements in staging practices.